Introduction
During the process of either chemical or radiation carcinogenesis, the progression of target cells through a premalignant to malignant state is accompanied by a variety of morphological, cytological, and biochemical alterations. Presumably, these phenotypic changes result from either qualitative alterations in encoded gene products or changes in the levels of expression of cellular genes. One class of cellular genes that is known to be altered during carcinogenesis and is thought to play a functional role in tumor formation is the cellular proto-oncogenes (1) (2) (3) . In addition to the proto-oncogenes, there is a class of cellular tumor-suppressor genes whose inactivation may be required for expression of the tumorigenic phenotype (4) . Both chemical carcinogens and ionizing radiation are known to induce the types of mutations that have been observed to activate proto-oncogenes to transforming oncogenes and to inactivate tumor-suppressor genes. These mutations can lead to structural changes in encoded gene products or loss of normal control of expression of these genes.
The mouse skin model of multistage carcinogenesis is an ideal system in which to identify critical target genes for the action of chemical or physical carcinogens. The process of malignant tumor formation in the model can be subdivided into distinct stages operationally defined as initiation, promotion, and progression. A single subcarcinogenic dose of a chemical carcinogen or ionizing radiation can be delivered to the target tissue, epidermis, and no tumors will appear unless the initiator is followed by repeated doses of a tumor promoter such as a phorbol ester. The majority of the tumors arising from initiation-promotion protocols are benign papillomas. In the progression stage, the benign papillomas progress to form malignant squamous cell carcinomas (SCCs), and a number of agents including some initiators, certain peroxides, and ionizing radiation can enhance the progression of benign to malignant tumors (5-7). In addition, there are epidermal cell cultures that represent each of the stages in the formation of the malignant SCCs. Therefore, questions can be asked about this model concerning the timing of certain gene alterations including proto-oncogene activation, tumorsuppressor gene inactivation, and differential expression of other cellular genes. In addition, potential functional roles for altered gene expression in tumor progression can be assessed using mammalian expression vectors and the various epidermal cell cultures that represent the stages in tumor formation.
Over the last 6 years, a number of laboratories have used this multistage model to study proto-oncogene ac-tivation (8) (9) (10) (11) (12) (13) (14) (15) (24, 27) . It has been proposed that this adduct may isomerize to yield an O6,7-(1'hydroxyetheno)guanine adduct that potentially could lead to a G:A transition mutation. Clearly, further work needs to be done in this area to determine why the observed A:T transversion mutation is predominant despite the lack of evidence for DNA-deoxyadenosine adducts.
Distinct Non-ras Transforming Genes in Ionizing Radiation-Initiated Mouse Skin Tumors
In addition to studying chemical carcinogen-initiated mouse skin tumors, we have focused on ionizing radiation-initiated, TPA-promoted skin tumors and dominant transforming genes. We found that ionizing radiation can act as a weak initiator (28,29) of malignant skin tumors (i.e., SCCs) when initiation is followed by TPA promotion. In addition, we observed that ionizing radiation was capable of inducing basal cell carcinomas, a tumor histology not seen with chemical agents in the mouse skin system. We have also observed that fractionated doses of accelerated electrons were effective in the third stage of tumor progression. DNAs from mouse skin tumors initiated with ionizing radiation including papillomas, SCCs, basal cell carcinomas (BCCs), and pilomatrixomas demonstrated dominant transforming activity by the production of transformed foci in the mouse recipient line, NIH 3T3 (30) . Dominant transforming activity was not found in DNA from normal epidermis or from the corresponding liver.
The NIH 3T3 transformants induced with SCC DNA grew in soft agar and formed tumors in nude mice.
Southern blot analyses of primary NIH 3T3 transformant DNAs carrying transforming genes from radiation-initiated SCCs indicated that the oncogenes responsible for the transformation of the recipient cells were not Ha-ras, Ki-ras, or N-ras, nor were they erbB, B-lym, met, neu, or raf. The transforming gene(s) transferred by DNA from four SCCs were further characterized by determining their sensitivity to digestion with a series of restriction enzymes. The results of these experiments indicated that there were at least three different transforming genes present in four SCCs initiated with ionizing radiation.
Our data suggest that the target gene(s) for oncogenic activation are different for chemical carcinogens and ionizing radiation. Support for this finding has recently been presented by Borek et al. (31) as well as by Krolewski and Little (32) . These workers have also detected distinct non-ras transforming genes in ionizing radiation-transformed rodent cells in culture. Perhaps it is not surprising that activation of the ras proto-oncogenes, and in particular the Harvey ras oncogene, was not identified with radiation-initiated mouse skin tumors as was consistently observed with chemically initiated mouse skin tumors (8) (9) (10) (11) (12) . The ras family of oncogenes is activated by point mutations, and the chemical initiating agents or their active metabolites are known to be relatively efficient point mutagens.
In contrast, ionizing radiation is a relatively weak point mutagen and instead induces larger genomic alterations. Goodhead (33) has compared the cross sections for ionizing radiation-induced mutations and in vitro transformation. From these studies he has suggested that the target for transformation is larger than a single gene and smaller than a chromosome and may involve more than one gene or chromosome. Rauth (34) has suggested that direct activation of a transforming gene may not be occurring. He speculated that a variety of genes that control stability of DNA or fidelity of DNA replication may be damaged by radiation and increase the probability of errors in DNA during subsequent rounds of DNA replication. Therefore, the likelihood of a second step In addition to studying dominant transforming genes as target genes activated during mouse skin carcinogenesis, we have also identified and characterized cellular genes whose expression is altered during tumor development (15) . To achieve this goal, we have used differential screening of cDNA libraries that were made from polyA + RNA isolated from SCCs induced by DMBA initiation and TPA promotion. The libraries were screened using cDNA probes made from RNA isolated from normal epidermis and SCCs. We isolated six cDNAs (mall to mal6) that identified distinct RNA transcripts that were overexpressed at different stages during skin tumor progression. To investigate a potential role of the mal genes in the process of skin carcinogenesis, we asked whether there was a correlation between the stage of tumor development and the level of expression of the different mal genes. In addition, we sequenced the cDNAs for the mal genes and searched gene sequence data bases for homology or identity with known genes.
Our work to date has focused on the mall to mal4 genes. The mall gene was found to be overexpressed in both benign and malignant skin tumors in comparison to normal adult epidermis (15, 35 Recent studies suggest a role for cellular retinol-binding protein in carcinogenesis (37) (38) (39) . Several workers have shown that squamous cell carcinomas of the head and neck contained increased levels of cellular retinolbinding protein compared to normal tissue. Since retinol inhibits terminal differentiation of keratinocytes, it has been suggested that the increased CRBP levels in squamous cell carcinomas may cause the decreased terminal differentiation observed in these carcinoma cells as compared with normal keratinocytes. Whether the tumorspecific overexpression of the mall gene may be linked to similar defective processes involved in tumor de-differentiation and cellular proliferation has to be determined by further experiments.
We have found that the mal2 gene transcripts are also overexpressed in both benign and malignant skin tumors. Our expression data have shown that there is a higher steady-state level of mal2 transcripts in benign papillomas that are autonomous (i.e., no longer require promoter treatment) compared to papillomas that are dependent on continued tumor promoter treatment (35) . Sequencing of a ma12 cDNA and a ma12 genomic clone has recently revealed identity with the sequence for a mouse hyperproliferative keratin, K-6 (D. R. Roop, personal communication). The mal3 cDNA used in probing of Northern blots has revealed multiple hybridizing bands. The intensity and pattern of these mal3-related bands or transcripts changed during tumor development. In normal adult epidermis, low steady-state lev-els of three transcripts were detected (i.e., 1.3, 2.3, and 2.9 kb). In benign papillomas, the 1.3 and 2.3 kb transcripts were overexpressed, whereas the largest 2.9 kb transcript was not detectable. In malignant SCCs, this largest transcript related to mal3 was always overexpressed, whereas the 2.3 kb transcript either was absent or was expressed at a lower level.
Sequencing of a full-length mal3 cDNA has shown identity with the highly conserved coding region of the ubiquitin gene (40) . Our cDNA sequence contained 96 bases of 5' noncoding region and 152 bases of 3' noncoding region. We have used both 5' and 3' specific oligonucleotide probes to determine that the cDNA that we cloned and sequenced corresponds to the ubiquitin gene (which encodes four tandem open reading frames of the ubiquitin monomeric protein) whose transcribed message is the 1.3 kb transcript that is overexpressed in both papillomas and SCCs compared to normal epidermis (21) . One of the six mal cDNA sequences, mal4, detected 1.9 kb transcripts that were expressed at levels 10-fold higher in SCCs in comparison to normal epidermis. A full-length cDNA for mal4 was obtained from a XgtlO cDNA library made from an SCC-producing cell line, PDVc57. DNA sequencing of this full-length mal4 cDNA revealed identity with the mouse 3-actin cDNA. Southern analysis of DNAs from normal epidermis, papillomas, and SCCs showed no evidence for amplification or gross rearrangement of the ,B-actin gene during tumor progression.
The RNA-RNA hybrid protection assay was used to screen for the expression of mutated 1-actin(s) in mouse skin tumors. No evidence for a mutation was obtained in the benign and malignant skin tumors that were examined. Fluorescence microscopy of tumor sections stained with rhodamine-conjugated phalloidin showed a peripheral pattern of F-actin localization with no gross differences between papillomas and SCCs. We also found approximately equal amounts of P-actin protein detected by two-dimensional gel electrophoresis and extracted from normal epidermis, papillomas, or SCCs.
These results indicated that the overexpression of P- 
Expression Pattern of the Transin Gene during Mouse Skin Tumor Progression
The rodent transin gene encodes an oncogene-inducible protein that has been shown to be a rodent homologue (16) of an extracellular matrix-degrading metalloproteinase known as stromelysin (42) . The rat transin or stromelysin cDNA was originally cloned because of its selective expression in polyoma virus-transformed rat fibroblast cells and lack of expression in untransformed parental cells (43) . Later studies indicated that stromelysin was present in cell lines transformed by a number of different oncogenes. These results prompted us to study the expression pattern of the stromelysin gene in mouse skin tumors produced in an initiationpromotion protocol (16) .
When RNA was isolated from tumors resulting from DMBA initiation and TPA promotion, stromelysin transcripts were detectable in 73% of the SCCs, but only 6% of the papillomas expressed low levels of stromelysin. Similar results were obtained with tumors initiated by N-methyl-N-nitroso-N'-nitroguanidine (MNNG) and promoted with TPA. When mice were treated with repeated applications of MNNG, a protocol which produces malignant tumors with a high probability of invading and metastasizing, 100% of the malignant tumors contained very high levels of stromelysin transcripts (44) . In relation to the overexpression of the stromelysin gene in invasive and metastatic skin tumors, it is of interest that stromelysin when activated can degrade fibronectin, laminin, proteoglyeans, gelatins, and to some extent collagen types III, IV, and V (45). These protein substrates are found in basement membrane that separates the epidermis from the dermis and must be transversed by malignant skin tumor cells for both invasion and metastasis to occur.
In addition to finding constitutive expression of the stromelysin gene in malignant skin tumors, we have also observed transient induced expression of the gene in phorbol-ester-treated normal mouse epidermis (17) . This response in terms of steady-state level of stromelysin message is transient, with peak levels occurring 12 to 18 hr after TPA treatment and reduced to background levels by 24 hr. Stromelysin expression is also stimulated by the incomplete second-stage tumor promoter 12-O-retinoylphorbol-13-acetate (RPA) but not induced by ethylphenyl propiolate, a nontumor promoting, hyperplastic agent. The stromelysin transcripts are localized to the basal cells of the TPA-stimulated epidermis. These results suggested that the transient induction of stromelysin during tumor promotion is a phorbol-ester-specific response and that it is not a result of the proliferative response to tumor promoters.
Our concept of the role of stromelysin in tumor progression is summarized as follows. Initiation of mouse skin with chemical carcinogens results in the activation of the Harvey ras oncogene in a small population of epidermal cells. These cells with the activated ras oncogene are thought to be "initiated" cells that undergo clonal expansion under the influence of a tumor pro-moter to give rise to a benign papilloma. Repeated treatment with the tumor promoter also results in repeated, transient elevations in stromelysin. Papillomas can be classified by their behavior after withdraw from tumor promoter treatment. "Dependent" papillomas are dependent on continuous promoter treatment or they will regress, whereas "autonomous" papillomas are no longer dependent on promoter treatment. Since a small percentage of papillomas contain stromelysin transcripts, we speculate that these tumors may have been "autonomous" and premalignant. Stromelysin expression may be constitutive in these premalignant tumors and no longer dependent on tumor promoter treatment. Conversion to malignant tumors is usually accompanied by constitutive expression of stromelysin. The reason for the constitutive expression of stromelysin in malignant SCCs is not because of either amplification or gross rearrangement of the stromelysin gene (44) . Since the tumors with the greatest probability of becoming invasive and metastatic have the greatest probability of expressing high levels of stromelysin, we speculate that this enzyme plays a causal role in promoting invasion through basement membrane barriers. Experiments being conducted in our laboratory are testing the hypothesis that the overexpression of the stromelysin gene is both necessary and sufficient for progression of benign papilloma cells to malignant tumor cells and the hypothesis that the overexpression of this gene is necessary but not sufficient for progression.
